Page last updated: 2024-12-06

nafimidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nafimidone is a synthetic, non-narcotic analgesic. It is a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2), which is responsible for the production of prostaglandins, inflammatory mediators involved in pain and inflammation. Nafimidone has been studied for its potential therapeutic effects in a variety of conditions, including pain, inflammation, and cancer. It has shown promising results in preclinical studies, but it has not yet been approved for use in humans. Nafimidone is a prodrug, meaning that it is converted to its active form in the body. The synthesis of Nafimidone involves several steps, including the reaction of a substituted aniline with a benzoyl chloride derivative. The resulting amide is then treated with a Grignard reagent to form the corresponding ketone. The final step in the synthesis is the reduction of the ketone to the desired alcohol. '

nafimidone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51200
CHEMBL ID416801
SCHEMBL ID1817018
MeSH IDM0116271

Synonyms (27)

Synonym
2-imidazol-1-yl-2'-acetonaphthone
2-(1h-imidazol-1-yl)-1-(1-naphthalenyl)ethanone
nafimidonum [latin]
1-(2-naphthoylmethyl)imidazole
nafimidone
brn 0523776
ethanone, 2-(1h-imidazol-1-yl)-1-(1-naphthalenyl)-
nafimidone [inn]
nafimidona [spanish]
CHEMBL416801
2-imidazol-1-yl-1-naphthalen-2-ylethanone
hzu3iq1eww ,
64212-22-2
nafimidonum
5-23-04-00380 (beilstein handbook reference)
unii-hzu3iq1eww
nafimidona
nafimidone [mart.]
ITPVLJQRUQVNSD-UHFFFAOYSA-N
SCHEMBL1817018
DTXSID80214426
1-(1-naphthyl)-2-(1h-imidazol-1-yl)ethanone
FT-0768480
1-(2-naphthyl)-2-(imidazol-1-yl)ethanone
Q6958175
2-(1h-imidazol-1-yl)-1-(naphthalen-2-yl)ethan-1-one
EN300-18563699

Research Excerpts

Overview

Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT)

ExcerptReferenceRelevance
"Nafimidone is a new antiepileptic drug which may be effective in partial onset seizures. "( Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy.
Gunawan, S; Treiman, DM, 1987
)
2.04
"Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT). "( Efficacy of nafimidone in the treatment of intractable partial seizures: report of a two-center pilot study.
Barber, KO; Ben-Menachem, E; Cereghino, JJ; McCormick, KB; Ojemann, L; Swisher, K; Treiman, DM; White, BG; Wilensky, AJ; Yerby, M,
)
1.95

Bioavailability

ExcerptReferenceRelevance
" Systemic clearance of nafimidone from plasma after iv administration was approximately 2 times higher than hepatic blood flow in rats, and the oral bioavailability was 15%."( Disposition of nafimidone in rats.
Chaplin, MD; Graham, DJ; Hall, DJ; Hama, KM; Kurz, L; Smith, SA,
)
0.79

Dosage Studied

ExcerptRelevanceReference
" within 30 min of dosing before electrical stimulation."( The anticonvulsant action of nafimidone on kindled amygdaloid seizures in rats.
Albertson, TE; Walby, WF,
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID112801Effective dose in mice by horizontal screen assay (administered orally); No effect at highest dose of 400 mg/kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID40680In vitro displacement of [3H]flunitrazepam binding to cortical membranes at 5e-5M concentration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID112168Effective dose to produce anticonvulsant activity using maximal electroshock assay (MES) evaluated in mice after oral administration1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Imidazole anticonvulsants: structure-activity relationships of [(biphenylyloxy)alkyl]imidazoles.
AID112808Effective dose in mice by pentylenetetrazole assay (administered subcutaneously)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID119413Potentiation of hexobarbital-induced sleeping time in mice1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID1312151Anticonvulsant activity in patient assessed as improvement in seizure control at 600 mg/day administered up to 1 year2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID40681In vivo displacement of [3H]flunitrazepam binding to rat cortical membranes after 20 mg/kg ip dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID122339Compound was tested for time to peak anticonvulsant effect (TPE)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID112804Effective dose in mice by maximal electroshock assay, administered orally1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (50.00)18.7374
1990's3 (18.75)18.2507
2000's1 (6.25)29.6817
2010's3 (18.75)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.21 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]